Pacira BioSciences (PCRX) Revenue Growth (3y) (2013 - 2026)
Pacira BioSciences (PCRX) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.95 Bn | 88.09 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.88 Bn | 32.14 Bn | 1.97 Bn | 2.84% |
| 3 | Zoetis | 32.64 Bn | 30.70 Bn | 1.62 Bn | 4.19% |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | -4.46% |
| 5 | United Therapeutics | 23.04 Bn | 20.88 Bn | 648.10 Mn | 15.52% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.37 Bn | 18.57 Bn | 1.16 Bn | -2.00% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.45 Bn | 800.70 Mn | 24.66% |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | 2.94% |
| 10 | Pacira BioSciences | 1.08 Bn | 880.35 Mn | 140.96 Mn | 3.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.42% |
| Dec 31, 2025 | 33.89% |
| Sep 30, 2025 | 2.34% |
| Jun 30, 2025 | 2.25% |
| Mar 31, 2025 | 2.26% |
| Dec 31, 2024 | 5.56% |
| Sep 30, 2024 | 9.69% |
| Jun 30, 2024 | 9.50% |
| Mar 31, 2024 | 11.98% |
| Dec 31, 2023 | 11.44% |
| Sep 30, 2023 | 11.74% |
| Jun 30, 2023 | 30.93% |
| Mar 31, 2023 | 14.91% |
| Dec 31, 2022 | -81.92% |
| Sep 30, 2022 | 16.95% |
| Jun 30, 2022 | 18.19% |
| Mar 31, 2022 | 20.05% |
| Dec 31, 2021 | 18.73% |
| Sep 30, 2021 | 15.24% |
| Jun 30, 2021 | 17.26% |